Compare LXFR & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LXFR | EDIT |
|---|---|---|
| Founded | 1898 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.4M | 432.8M |
| IPO Year | 2002 | 2016 |
| Metric | LXFR | EDIT |
|---|---|---|
| Price | $19.23 | $2.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.30 |
| AVG Volume (30 Days) | 133.4K | ★ 3.8M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $384,600,000.00 | $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.01 | N/A |
| P/E Ratio | $146.77 | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $11.19 | $1.66 |
| 52 Week High | $19.25 | $4.54 |
| Indicator | LXFR | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 78.91 | 50.21 |
| Support Level | $11.64 | $2.65 |
| Resistance Level | N/A | $3.27 |
| Average True Range (ATR) | 0.71 | 0.24 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 86.64 | 43.09 |
Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.